爱普列特治疗良性前列腺增生的疗效观察

目的 :评价爱普列特 (Epristeride)治疗良性前列腺增生 (BPH)的安全性、有效性。 　方法 :14 1例诊断为BPH的病人 ,年龄 5 0～ 83岁 ,平均 (6 6 .18± 6 .4 1)岁。给予爱普列特片 5mg ,2次 /d口服 ,共 12 0d。以国际前列腺症状评分 (IPSS)、最大尿流率 (Qmax)、前列腺体积 (V)及剩余尿 (Ru)的变化率评分综合判断疗效。疗效分类 :显效、有效、改善和无效 ,以显效和有效计算有效率。　结果 :139例参加有效率统计 ,其中 :显效 37例 (2 6 .6 2 % )、有效 76例 (5 4 .6 8% )、改善 2 0例 (14 .39% )、无效 6例 (4.32 % ) ,有效率为 81.2 9%。不良反应共 7例 (5 .0 4 % ) :皮疹1例 (0 .72 % )、胃肠道反应 1例 (0 .72 % )、失眠 1例 (0 .72 % )、耳鸣 1例 (0 .72 % )、勃起功能障碍 3例 (2 .16 % ) ,2例因不良反应而停药 (1.4 4 % ) ,不参加统计有效率。未出现有临床意义的实验室指标异常。　结论 :爱普列特片是治疗BPH安全、有效的药物。

The Clinical Efficacy of Epristeride in the Treatment of Benign Prostatic Hyperplasia

OBJECTIVES: To estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH). METHODS: One hundred and fourty-one BPH patients, aged from 50 to 83 years old [(66.18 +/- 6.41) yr], were given Epristeride tablets 5 mg p.o., twice daily for 120 days. To synthetically estimate the efficacy by the changing rate of international prostate symptom score (IPSS), maximum flow rate (Qmax), the volume of prostate (V) and the residual urine (Ru). RESULTS: The total efficacy was 81.29%. The adverse reactions include 1 case (0.72%) of exanthem, 1 case (0.72%) of nausea and vomiting, 1 case (0.72%) of insomnia, 1 case (0.72%) of tinnitus and 3 cases (2.16%) of erectile dysfunction. Two patients discontinued the treatment due to the side effects (1.44%). There was no clinical significantly abnormal laboratory index during the treatment. CONCLUSIONS: Epristeride tablets was safe and effective in the treatment of BPH.